Investor Presentaiton

Summary of Drive 2022 (1) SEKISUI Achieved record high net sales, net income, and EBITDA; despite a harsh business environment owing to such factors as the prolonged impact of COVID-19, undertook structural reforms while strengthening profitability to improve earning power ■ROE recovered to the 10% level; advanced ROIC management (JPY billion) Net sales Operating profit (margin) Net income FY2019 results 1,129.3 FY2022 results 1,242.5 FY2022 Medium-term plan 1,220.0 Difference +22.5 88.0 (7.8%) 91.7 (7.4%) 110.0 (9.0%) -18.3 58.9 69.3 70.0 -0.7 ROIC (%) 7.7% 7.6% 8.6% -1.0% ROE (%) 9.7% 10.0% 10.6% -0.6% Overseas sales (ratio) 274.7 (24%) 375.1 (30%) 320.0 (26%) +55.1 EBITDA 133.2 142.1 170.0 -27.9 By Segment HPP Housing UIEP Medical 19.9 20.8 14.7 13.3 14.0 14.4 12.7 11.5 10.9 8.3 OP Margin (%) 8.0 8.0 7.4 7.3 6.1 7.8 10.4 10.5 10.3 10.2 9.1 ROIC (%) 512.9 537.4 548.0 7.5 8.4 404.1 360.0 6.5 240.0 322.4 237.4 227.2 89.7 (JPY billion) 85.0 48.0 44.2 72.6 37.4 44.0 37.8 Net sales 32.8 15.5 17.1 20.0 12.5 12.5 9.2 Operating profit FY19 FY22 FY22 Before PF Medium-term reorganization Plan Fell short of operating profit plans due to the downturn in aircraft demand attributable to COVID-19 and deterioration in electronics market conditions FY19 FY22 FY22 Medium-term Plan FY19 Fell short of plans due to the prolonged impact of COVID-19, sluggish housing market conditions attributable to inflation, and soaring component costs FY22 FY22 Before PF Medium-term reorganization Plan Despite falling short of profit plans due to the surge in raw material prices and sluggish demand, progress in improving selling prices; record-high profits FY19 FY22 FY22 Medium-term Plan Achieved plans on the back of increased sales of COVID-19 diagnostics kits and growth in new pharmaceutical ingredients; record-high profits Copyright@ SEKISUI CHEMICAL CO., LTD. * HPP: High Performance Plastics Company, Housing: Housing Company, UIEP: Urban Infrastructure & Environmental Products Company 3

View entire presentation